TY - JOUR
T1 - The use of web analytics combined with other data streams for tailoring online vaccine safety information at global level: The Vaccine Safety Net's web analytics project
AU - Gesualdo, F.
AU - Marino, F.
AU - Mantero, J.
AU - Spadoni, A.
AU - Sambucini, L.
AU - Quaglia, G.
AU - Rizzo, C.
AU - Sahinovic, I.
AU - Zuber, P.L.F.
AU - Tozzi, A.E.
AU - group, the VSN-WAP study
N1 - Cited By :2
Export Date: 19 March 2021
CODEN: VACCD
Correspondence Address: Gesualdo, F.; Bambino Gesù Children's HospitalItaly; email: francesco.gesualdo@opbg.net
PY - 2020
Y1 - 2020
N2 - The Vaccine Safety Net's Web Analytics Project (VSN-WAP) was launched in October 2017 to monitor the behavior of users visiting websites belonging to the VSN, a global network of websites providing science-based information on vaccine safety. Participating websites could provide web metrics in two ways: through a Google Analytics (GA) script, which automatically forwarded metrics to a central account and through manual input (MI) of a reduced subset of metrics (Sessions, Page Views, New Users, Bounce Rate, Views/Session and Average Session Duration), which were pooled with the metrics obtained through GA. Additional metrics were obtained from websites providing data through Google Analytics (Country, Age, Sex, Device). We report results from February 2018 to March 2019. In March 2019, 32 websites were participating in the project (21 through GA, 11 through MI). From February 2018 to March 2019 we recorded 22,471,535 sessions, with 38,307,349 page views. Sessions, New Users and Page views progressively increased, Views/Session, Bounce Rate and Average Session Duration remained stable. Most users were female (68%) and belonged to the 25–34 age range (37%), followed by 35–44 (22%) and 18–24 (19%). Fifty-four percent of users connected from a mobile device, 42% from a desktop and 4% from a tablet. Digital media monitoring techniques can provide insights on the characteristics of users with a specific interest in vaccines. These data can be exploited to improve the performance of websites providing information on vaccines to the general public. © 2020
AB - The Vaccine Safety Net's Web Analytics Project (VSN-WAP) was launched in October 2017 to monitor the behavior of users visiting websites belonging to the VSN, a global network of websites providing science-based information on vaccine safety. Participating websites could provide web metrics in two ways: through a Google Analytics (GA) script, which automatically forwarded metrics to a central account and through manual input (MI) of a reduced subset of metrics (Sessions, Page Views, New Users, Bounce Rate, Views/Session and Average Session Duration), which were pooled with the metrics obtained through GA. Additional metrics were obtained from websites providing data through Google Analytics (Country, Age, Sex, Device). We report results from February 2018 to March 2019. In March 2019, 32 websites were participating in the project (21 through GA, 11 through MI). From February 2018 to March 2019 we recorded 22,471,535 sessions, with 38,307,349 page views. Sessions, New Users and Page views progressively increased, Views/Session, Bounce Rate and Average Session Duration remained stable. Most users were female (68%) and belonged to the 25–34 age range (37%), followed by 35–44 (22%) and 18–24 (19%). Fifty-four percent of users connected from a mobile device, 42% from a desktop and 4% from a tablet. Digital media monitoring techniques can provide insights on the characteristics of users with a specific interest in vaccines. These data can be exploited to improve the performance of websites providing information on vaccines to the general public. © 2020
KW - Internet
KW - News monitoring
KW - Vaccine communication
KW - Vaccine safety
KW - Web analytics
KW - vaccine
KW - access to information
KW - age
KW - Article
KW - automation
KW - demography
KW - drug safety
KW - gender
KW - information dissemination
KW - online system
KW - priority journal
U2 - 10.1016/j.vaccine.2020.07.070
DO - 10.1016/j.vaccine.2020.07.070
M3 - Article
VL - 38
SP - 6418
EP - 6426
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 41
ER -